Vericel Stock Price, News & Analysis

Vericel Corporation (NASDAQ:VCEL) appointed Jonathan Siegal as Principal Accounting Officer, effective February 16, 2022. Siegal, previously Vice President and Corporate Controller, joined Vericel in September 2021 and brings over 20 years of accounting experience across multiple industries. He held various leadership roles, including Global Controller for Lantheus Medical Imaging. CFO Joe Mara commended Siegal's extensive background in strengthening Vericel's finance team, reflecting the company’s commitment to enhancing its financial leadership.

Vericel Corporation (NASDAQ:VCEL) reported a 26% revenue growth in 2021, achieving total net revenue of $156.2 million. For Q4 2021, net revenue was $47.6 million, a 5% increase year-over-year. While MACI revenue reached $111.6 million and Epicel revenue hit $41.5 million, the company reported a net loss of $7.5 million for the year. Looking ahead, Vericel anticipates 2022 revenues between $178 million and $189 million with a gross margin of approximately 70%. A conference call is scheduled for today at 8:30 AM ET.

Vericel Corporation (NASDAQ:VCEL) announced a conference call on February 24, 2022 at 8:30 AM EST to discuss its fourth-quarter 2021 financial results and business highlights. The call will be accessible via the Investor Relations section of their website. Vericel specializes in advanced therapies in sports medicine and severe burn care, offering products like MACI® and Epicel®. A replay of the call will be available until February 28, 2022.

Vericel Corporation (NASDAQ:VCEL) has announced a long-term lease for a new 125,000 square foot facility in Burlington, Massachusetts, which will serve as its advanced cell therapy manufacturing and corporate headquarters. This state-of-the-art facility will enhance the company’s manufacturing capacity for its products MACI® and Epicel®, supporting long-term revenue growth. Expected completion is in 2024, with production starting in 2025. The facility aims to meet LEED Gold and Fitwel Level 2 certifications, reinforcing the company’s commitment to environmentally responsible operations.

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. Eastern Time. This esteemed conference is a significant platform for healthcare companies to share insights and updates.

A webcast of the presentation will be accessible on the Investor Relations section of Vericel's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.

Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18 at 10:00 AM ET. This event aims to showcase advancements in medical technology and health services.

A webcast of the presentation will be accessible on the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.

Vericel Corporation (NASDAQ: VCEL) reported third quarter 2021 net revenue of $34.5 million, a 7% increase from $32.3 million in Q3 2020. Year-to-date revenue rose 38% to $108.6 million. Notably, MACI revenue was $23.9 million, and Epicel revenue was $9.8 million. The company faced a net loss of $4.9 million or $0.11 per share, contrasting with net income of $3.6 million in Q3 2020. Gross margin decreased to 64%, down from 70% the previous year. The company adjusted its full-year revenue guidance to reflect a projected increase of 27%-30%.

Vericel Corporation (NASDAQ:VCEL) has announced a webcast and conference call to discuss its third-quarter 2021 financial results and business highlights. The call is scheduled for November 9, 2021, at 8:30 AM EDT. Investors can access the call live via the company's Investor Relations website. Vericel operates in advanced therapies for sports medicine and severe burn care, marketing two cell therapy products: MACI® and Epicel®. The company also holds the exclusive North American commercial rights for NexoBrid®, aimed at severe burn treatment.

Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference. The event is scheduled for Monday, September 13, 2021, at 4:15 p.m. Eastern Time. Investors can access the webcast through the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®. For further details, visit www.vcel.com.